VBL Therapeutics, Ltd. (VBLT)

Oncology Corporate Profile

Stock Performance

3.2300
0.0300

HQ Location

6 Jonathan Netanyahu St.
Or Yehuda, Israel 60376

Company Description

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer.

Website: http://www.vblrx.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
VB-111anti angiogenic agentGlioblastoma Multiforme (GBM)III
VB-111anti angiogenic agentOvarian cancerII
VB-111anti angiogenic agentThyroid cancerII
VB-111anti angiogenic agentVarious cancer typesI

View additional information on product candidates here »

Source: http://www.vblrx.com

Recent News Headlines

5/27/2017 06:19 am

5/27/2017 06:19 am

5/27/2017 06:19 am

5/27/2017 06:19 am

5/15/2017 06:19 am

5/15/2017 06:19 am

5/15/2017 06:19 am

5/15/2017 06:19 am

5/15/2017 12:19 am

5/15/2017 12:19 am

5/15/2017 12:19 am

5/15/2017 12:19 am

5/11/2017 12:19 am

5/7/2017 06:19 am

5/1/2017 12:19 pm

4/25/2017 12:19 am

4/25/2017 12:19 am

4/25/2017 12:19 am

4/24/2017 12:19 pm

4/20/2017 12:19 pm

VBL Therapeutics Presents New Data Supporting Use of Lecinoxoids in NASH

4/3/2017 11:00 am

[GlobeNewswire] - Phase 2 Study of VB-201 Shows Reduction in Liver Enzymes. Data Presented Today at H.C. Wainwright Annual NASH Investor Conference.

VBL Therapeutics to Present at the H.C. Wainwright NASH Investor Conference

3/28/2017 11:00 am

[GlobeNewswire] - TEL AVIV, Israel, March 28, 2017-- VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced ...